clinical trial · NCT00835549
Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting
Teva Pharmaceuticals USA·phase1·completed·n = 32
HealthyCefdinir for oral suspension 250 mg/5mLOMNICEF® for oral suspension 250 mg/5mL
brief summary
The objective of this study is to compare the relative bioavailability of cefdinir for oral suspension 250 mg/5mL (manufactured and distributed by TEVA Pharmaceuticals USA) with that of OMNICEF® for oral suspension, 250 mg/5mL (Abbott) in healthy, adult, non-smoking subjects under non-fasting conditions.
started
Mar 1, 2005
primary completion
Mar 1, 2005
completion
Mar 1, 2005
last updated
Aug 20, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
A Relative Bioavailability Study of Cefdinir for Oral Suspension 250 mg/5mL Under Non-Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol